Abstract 336P
Background
Immune checkpoint inhibitor (ICI) plus Chemotherapy has now become the new standard treatment for non-small-cell lung cancer (NSCLC). However, little is known about comparison of ICI plus Chemotherapy and ICI monotherapy in the real world.
Methods
Patients with PD-L1-positive, advanced NSCLC treated with pembrolizumab plus chemotherapy (C group) or pembrolizumab monotherapy (M group) at Sendai Kousei Hospital between May 2015 to June 2019 were included in our study. C group received different treatments depending on histology: Patients with squamous NSCLC were received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]–paclitaxel plus pembrolizumab followed by pembrolizumab maintenance therapy. Patients with non-squamous NSCLC were received pemetrexed and a platinum-based drug plus pembrolizumab followed by pembrolizumab plus pemetrexed maintenance therapy. Two groups were evaluated with respect to adverse event (AE) profiles, objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS).
Results
The following were observed: patient background (C group/ M group) number of cases 13/ 38 cases, median age 64/ 73 years old, male 76.9/71.1 %, Performance Status 0 or 1/ 2/ ≧3 (13/ 0/ 0) / (36/ 2/ 0), median observation period 5.1/ 7.4 months, development of AEs 100/ 84.2 %, development of immune-rerated AEs (irAEs) 61.5/ 84.2 %, development of irAEs ≥ grade 3 7.7/ 21.1 %. There was no significant difference in the ORR (38.5/ 55.2 %; p = 0.199) and DCR (100/89.5 %; p = 0.561) between two groups. Three months PFS were 100 % in combination group and 76.3 % in monotherapy group. Median PFS wasn’t significant different between the two groups (5.9/ 9.2 months; p = 0.193). PFS within 3 months of treatment start of C group tended to be better than M group.
Conclusions
Median PFS wasn’t significantly different between the two groups, probably due to the short observation period. PFS within 3 months of treatment start of C group tended to be better than M group. C group had more AEs than M group. However, the frequency of severe irAEs in C group was similar to M group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Sugawara: Honoraria (self): Ono Pharmaceutical; Honoraria (self): Bristol-Myers Squib; Honoraria (self): MSD; Honoraria (self): AstraZeneca; Honoraria (self): Chugai Pharma; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): Pfizer; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Eli Lilly and Company; Honoraria (self): Novartis; Honoraria (self): Kyowa Hakko Kirin. Y. Toi: Honoraria (self): Ono Pharmaceutical; Honoraria (self): MSD; Honoraria (self): AstraZeneca. Y. Kawashima: Honoraria (self): Chugai Pharma. A. Nakamura: Honoraria (self): MSD; Honoraria (self): Chugai Pharma; Honoraria (self): AstraZeneca. S. Yamanda: Honoraria (self): Kyowa Hakko Kirin; Honoraria (self): Novartis; Honoraria (self): AstraZeneca; Honoraria (self): Taiho Pharmaceutical. Y. Kimura: Honoraria (self): Nippon Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases
Presenter: Masatsune Shibutani
Session: Poster display session
Resources:
Abstract
108P - Influence of liver metastasis locations on overall survival in patients with colorectal cancer
Presenter: Takayuki Sone
Session: Poster display session
Resources:
Abstract
109P - 18F-FDG PET/CT textural features as predictors of outcomes in patients with primary advanced colorectal cancer
Presenter: Jing Yang
Session: Poster display session
Resources:
Abstract
110P - D3 lymph node dissection may be necessary in clinical stage I right colon cancer
Presenter: Woong Bae Ji
Session: Poster display session
Resources:
Abstract
111P - Is preoperative chemoradiotherapy necessary for all patients with upper rectal cancer: One center retrospective study
Presenter: Jasur Madyarov
Session: Poster display session
Resources:
Abstract
112P - A retrospective analysis of the association between perioperative, post adjuvant carcinoembryonic antigen level and prognosis in stage III colorectal cancer
Presenter: Ryotaro Kozuki
Session: Poster display session
Resources:
Abstract
113P - Dicer contributes to chemoresistance in colorectal cancer via regulating a set of miRNAs and their downstream mRNAs
Presenter: Liang-Yi Hung
Session: Poster display session
Resources:
Abstract
114P - Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial
Presenter: Jun Zhu
Session: Poster display session
Resources:
Abstract
115P - Expression of Ki-67 as a prognostic factor in patients with colorectal cancer
Presenter: Kuantkan Zhabagin
Session: Poster display session
Resources:
Abstract
116P - Clinical significance and converionrate relevance of RAS genetic mutation analysis for unresectable colorectal liver metastases: A single-center retrospective study
Presenter: Meiling Ji
Session: Poster display session
Resources:
Abstract